J&J Pauses Coronavirus Vaccine Study Due To Participant’s Unexplained Illness; Media Outlets Cover Other Aspects Of Vaccine, Treatment Research, Public Opinion
STAT: Johnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant
“The study of Johnson & Johnson’s Covid-19 vaccine has been paused due to an unexplained illness in a study participant. A document sent to outside researchers running the 60,000-patient clinical trial states that a ‘pausing rule’ has been met, that the online system used to enroll patients in the study has been closed, and that the data and safety monitoring board — an independent committee that watches over the safety of patients in the clinical trial — would be convened. The document was obtained by STAT. Contacted by STAT, J&J confirmed the study pause, saying it was due to ‘an unexplained illness in a study participant.’ The company declined to provide further details…” (Herper, 10/12).
Axios: Vaccine initiative now covers almost entire world, but not U.S. or Russia (Lawler, 10/12).
Becker’s Hospital Review: Operation Warp Speed czar: Vaccine approval likely to be sought around Thanksgiving (Adams, 10/23).
The Hill: Abbott gets emergency authorization for new COVID antibody test (Weixel, 10/12).
New York Times: The Race for a Super-Antibody Against the Coronavirus (Mandavilli, 10/12).
New York Times: First, a Vaccine Approval. Then ‘Chaos and Confusion’ (Zimmer, 10/12).
New York Times: Heidi Larson Knows How to Build Trust in Vaccines (Anderson, 10/13).
Reuters: WHO says 180-plus countries including China committed to vaccine effort (Miller, 10/12).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.